Search Results
Your search for early matches 10332 pages
Showing 2751 - 2800Expert Point of View: David Cunningham, MD
David Cunningham, MD, Consultant Medical Oncologist, Head of the Gastrointestinal and Lymphoma Unit, and Director of Clinical Research at The Royal Marsden in London and Surrey in the United Kingdom, discussed CheckMate 6481 as well as the ESCORT-1st study of the PD-L1 inhibitor camrelizumab in...
Rates of Adverse Reactions to the Moderna mRNA-1273 COVID-19 Vaccine in Patients With Cancer and Recent Radiotherapy
In an Italian single-center study reported in a letter in The Lancet Oncology, Scoccianti et al found that patients who underwent radiotherapy for cancer within the 6 months prior to receipt of the Moderna mRNA-1273 COVID-19 vaccine did not experience a difference in adverse reactions to the...
Neoadjuvant Atezolizumab Under Study for Resectable Pleural Mesothelioma
Neoadjuvant atezolizumab combined with pemetrexed and cisplatin, followed by surgical resection and maintenance atezolizumab, proved safe and feasible and offered hints of benefit in patients with resectable pleural mesothelioma. Results from a small multicenter study were presented by Boris...
Radical Cystectomy: Early-Stage Micropapillary Bladder Cancer Outcomes Similar to Late-Stage Conventional Urothelial Carcinoma
A study presented by Kevin Ginsburg, MD, and colleagues at the American Urological Association 2021 Annual Meeting has found that among patients treated with radical cystectomy, those with cT1 micropapillary bladder cancer had similar or worse oncologic outcomes compared with patients with cT2...
Racial Disparities Among Men With Prostate Cancer
Despite great strides in prostate cancer treatment over the past several years, racial disparities in care persist, according to new data presented during the 2021 Annual Meeting of the American Urological Association (AUA). Three studies highlighting this topic were presented during a virtual...
Guideline Update Addresses Treatments for HER2-Negative Advanced Breast Cancer
In light of findings from multiple recent clinical trials in HER2-negative metastatic breast cancer, ASCO has revised its treatment recommendations to inform more evidence-based care for metastatic breast cancer.1 “This guideline update provides important clinical guidance about the new use of...
COVID-19 Pandemic Spurs Quick Uptick in Telehealth Adoption, ASCO Provides Guidance for Oncologists
ASCO recently released a new set of standards and practice recommendations specific to telehealth in oncology.1 These new standards provide guidance for which patients can be seen through telehealth; the establishment of the doctor-physician relationship; the role of allied health professionals and ...
ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL
Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...
Prevalence of Germline BRCA Mutations in Indian Women With Ovarian Cancer
Ovarian cancer is one of the most common gynecologic cancers, with 313,959 new cases and 207,252 deaths reported worldwide in 2020.1 Since there is no effective screening method, ovarian cancer in general is diagnosed in its late stage. The 5-year survival rate in women with ovarian cancer is less...
Lutetium-177–PSMA-617: A First-in-Class Radioligand Therapeutic in Metastatic Prostate Cancer
Based on the findings of the phase III VISION trial, reported by Sartor et al1 and summarized in this issue of The ASCO Post, lutetium-177–PSMA-617 (LuPSMA) is the first of the prostate-specific membrane antigen–targeted cancer theranostics to demonstrate a survival-prolonging benefit for men with...
Adding LuPSMA to Standard Care Improves Outcomes in Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Oliver Sartor, MD, of the School of Medicine, Tulane University, and colleagues, the phase III VISION trial has shown prolonged progression-free and overall survival with lutetium-177–PSMA-617 (LuPSMA) radioligand therapy plus standard care vs...
Cancer Is Trying to Steal My Body, but I Will Not Allow It to Steal My Joy
Until I was diagnosed with HER2-positive, estrogen receptor–positive/progesterone receptor–positive de novo metastatic breast cancer in 2009, I didn’t realize that Black women could get the disease. Although my mother died of metastatic breast cancer 5 years earlier when she was 65, she was the...
Recommendations From ASCO for Discussing Patients’ Goals of Care Through Survivorship to End of Life
In 2017, ASCO published its consensus guideline to provide guidance on how oncologists can use effective communication to maximize the patient-clinician relationship, patient and clinician well-being, and family well-being as well as form a trusting relationship with patients through empathy and...
Improving End-of-Life Discussions With Patients Who Have Advanced Cancer
Although studies have shown that patients with advanced cancer want their oncologists to discuss their advance care plans with them, fewer than half of those patients have that conversation. The reasons are many, including the difficulty many oncologists have in initiating conversations about...
Study Finds Lower Income Eligibility Limits for Medicaid Associated With Worse Long-Term Survival for Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living ...
An Oncologist’s Prescription: Humanity and Love
Cancer care is one of the most technical and scientific of all medical disciplines. Oncologists must keep abreast of a dizzying array of novel treatment options coming out of the laboratory while delivering empathetic care for the physical and emotional needs of their patients with cancer....
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
“Progress lies not in enhancing what is, but in advancing toward what will be.” —Khalil Gibran The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held virtually...
Pembrolizumab for High-Risk, Early-Stage Triple-Negative Breast Cancer
On July 26, 2021, pembrolizumab was approved for high-risk, early-stage, triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and continued as adjuvant treatment.1 Pembrolizumab was also granted regular approval in combination with chemotherapy for locally...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in South Africa
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in South Africa. The aim of this special feature is to highlight the global cancer burden for various countries of...
Assumptions, Data … and More Questions!
I read with great interest the results from the phase II ZUMA-12 study of axicabtagene ciloleucel, presented during the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 But the results raised several questions for me. Axicabtagene ciloleucel, an autologous anti-CD19...
Rates of Newly Diagnosed Cancer Among U.S. Patients During the First Full Year of the COVID-19 Pandemic
In a study of Quest Diagnostics data reported as a research letter in JAMA Network Open, Kaufman et al found significant decreases in monthly new cancer diagnoses during the first full year of the COVID-19 pandemic compared with the prepandemic period. As stated by the investigators, “We previously ...
Several Studies Show Rovalpituzumab Tesirine Is Ineffective Against SCLC
Four independent studies published in the Journal of Thoracic Oncology demonstrate that rovalpituzumab tesirine (Rova-T), a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), is not effective against small cell lung cancer (SCLC). An accompanying editorial by...
How COVID-19 Is Spotlighting the Role of Palliative Medicine
The COVID-19 pandemic has exposed the tragedy of patients dying in isolation, separated from family and friends to limit infection in hospital settings. The process has altered the experience of serious illness for patients and their loved ones, including their ability to grieve, share important...
Cell-Free DNA Analysis to Distinguish Development of Malignant Peripheral Nerve Sheath Tumors From Plexiform Neurofibromas
The inherited condition neurofibromatosis type 1, or NF1, is responsible for the development of benign tumors that grow along the nerves; in some individuals, however, these benign tumors transform into aggressive and malignant peripheral nerve sheath tumors. Determining whether this transformation ...
Gastrointestinal Oncologist Focuses on Both the Art and Science of Treating Patients With Cancer
Chloe Atreya, MD, PhD, was born and reared in Ann Arbor, Michigan. Her mother is a poet, and her father is a planetary physicist and a professor at the University of Michigan. “Some of my early memories that influenced my decision to go into medicine stem from conversations I had with my father...
Early-Stage Research on Dual-Action Estrogen Receptor Inhibitors for Breast Cancer
A set of compounds developed by scientists at Scripps Research target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. More information on these dual-mechanism estrogen receptor inhibitors was published by Min et...
Evandro de Azambuja, MD, PhD, Comments on the BERENICE Trial
The invited discussant for the BERENICE trial was Evandro de Azambuja, MD, PhD, Head of the Medical Support Team at the Institut Jules Bordet in Brussels. He concluded from the study that pertuzumab plus trastuzumab, combined with an anthracycline/taxane regimen given every 2 weeks or every 3...
Safety, Efficacy of Neoadjuvant Pertuzumab Plus Trastuzumab Maintained in Final Analysis of BERENICE Trial
Long-term cardiac safety and efficacy have been confirmed for pertuzumab plus trastuzumab in patients with early breast cancer, in an update of the phase II BERENICE trial reported at the 2021 ESMO Breast Cancer Virtual Congress.1 Chau T. Dang, MD, of the Breast Medicine Service at Memorial Sloan...
Study Examines Link Between in Utero Events and Risk of Colorectal Cancer in Adult Offspring
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research published by Murphy et al in the journal Gut. Obesity is already a well-established risk factor for colorectal cancer, and several studies suggest...
Inguinofemoral Radiotherapy vs Inguinofemoral Lymphadenectomy for Patients With Vulvar Cancer and Sentinel Node Metastasis
In the phase II GROINSS-V II study reported in the Journal of Clinical Oncology, Oonk et al found that inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in women with early-stage vulvar cancer and sentinel node micrometastasis but was associated with a higher...
Are Triplets Necessary for BRAF-Mutated Melanoma?
Where does triplet therapy fit in the treatment of patients with stage IV BRAF-mutated melanoma? Is there strong evidence for combining a BRAF inhibitor, MEK inhibitor, and checkpoint inhibitor? Ragini Kudchadkar, MD, Chair of the Protocol Review and Monitoring Committee at Winship Cancer Institute ...
Study Highlights Gaps Between Lung Cancer Treatment Recommendations and Real-World Use of Durvalumab
A recent study published by Ronden et al in JTO Clinical and Research Reports highlights the gap between treatment guidelines and real-world care with the monoclonal antibody durvalumab for patients with non–small cell lung cancer. Researchers studied treatment decision-making by three Dutch...
Liquid Biopsy Is Changing Colon Cancer Management
The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...
Two Studies Explore the Role of Primary Care Providers in Effective Cancer Care
Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers authored by University of Michigan Rogel Cancer Center researchers. Although each study analyzed different stages of...
Japanese Study Examines How Intervention Encourages Screening for Colorectal Cancer Among Patients With Schizophrenia
Cancer is a leading cause of mortality in patients with mental illnesses. Although individuals with mental illnesses are equally as vulnerable to cancer as the general population, they are at a much higher risk of cancer-related mortality. Owing to a lack of early screening in most cases, such...
Report Aims to Assess Contemporary Burden of Brain Tumors in the United States
A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...
ASCO and MASCC/ISOO Publish Joint Guideline on Prevention, Treatment of Salivary Gland Hypofunction and Xerostomia
A new joint ASCO guideline offers clinicians updated evidence-based recommendations for the prevention and treatment of salivary gland hypofunction and xerostomia caused by nonsurgical cancer therapies.1 The guidance was developed together by ASCO and the Multinational Association of Supportive...
I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering
Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
High Prevalence of Previously Undiagnosed Emphysema Among Individuals Undergoing Low-Dose CT Screening for Lung Cancer
In a prospective cohort study reported in Clinical Imaging, David Steiger, MD, of the Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, in New York, and colleagues in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in ...
New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer
ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...
Historic, Present, and Future Perspectives on Breast Cancer in Egypt
Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...
Low-Dose CT Screening for Lung Cancer and the Incidental Findings That May Improve Future Health
Every interaction with patients is an opportunity to change the course of their lives. In the context of screening for disease, every encounter is an opportunity to detect the precursors or early changes that signal early pathophysiology. Smoking status and age are the factors that currently...
Excess Cardiovascular Disease Risk in Patients With Early-Stage Lymphoma: Personalizing Radiotherapy Delivery
As reported in the Journal of Clinical Oncology by Cutter et al, an analysis from the UK NCRI RAPID trial of positron-emission tomography (PET)-directed therapy in patients with early-stage Hodgkin lymphoma indicated that the use of involved-field radiotherapy in PET-negative patients who had...
Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Early-Phase Study Rediscovers Potential Alternative to Methadone for Cancer Pain
Levorphanol was associated with improved pain and symptom control in patients with advanced cancer, according to data from an early phase I trial, reported by Akhila Reddy, MD, at the 2021 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)...
Eric Deutsch, MD, PhD, Comments on the Averectal and AVANA Trials in Rectal Cancer
Eric Deutsch, MD, PhD, Professor and Chair of Radiation Oncology at Gustave Roussy, Villejuif, France, commended the speakers for conducting trials whose results he found “very interesting.” The Averectal trial involved a short course of radiation with modified FOLFOX-6 (oxaliplatin, fluorouracil...
Prediction Models May Reduce False-Positives in Women With Dense Breasts Undergoing MRI Screening
Prediction models based on clinical characteristics and imaging findings may help reduce the false-positive rate in women with dense breasts who undergo supplemental breast cancer screening with magnetic resonance imaging (MRI), according to a study published by den Dekker et al in the journal...
